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A B S T R A C T
Introduction: Our goal was to perform a systematic review of the literature on the use of intravenous
lidocaine in adults for status epilepticus (SE) and refractory status epilepticus (RSE) to determine its
impact on seizure control.
Methods: All articles from MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane
Library, the International Clinical Trials Registry Platform (inception to November 2014), and gray
literature were searched. The strength of evidence was adjudicated using both the Oxford and GRADE
methodology by two independent reviewers.
Results: Overall, 13 studies were identiﬁed, with 11 manuscripts and 2 meeting abstracts. Seventy-six
adult patients were treated for 82 episodes of SE/RSE. Patients had varying numbers of anti-epileptic
drugs (AEDs), 1–12, on board prior to lidocaine therapy. During 69 of the 82 (84.1%) episodes of SE/RSE,
phenytoin was on board. The dose regimen of lidocaine varied, with some utilizing bolus dosing alone;
others utilizing a combination of bolus and infusion therapy.
Overall, 70.7% of seizures responded to lidocaine, with complete cessation and greater than 50%
reduction seen in 64.1% and 6.1% respectively. Patient outcomes were sparingly reported.
Conclusions: There currently exists level 4, GRADE C evidence to support the consideration of lidocaine
for SE and RSE in the adult population. Thus there is currently weak evidence to support the use of
lidocaine in this context. Further prospective studies of lidocaine administration in this setting are
warranted.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Refractory status epilepticus (RSE), deﬁned as the failure of
seizure response to a ﬁrst line benzodiazepine and second
line anti-epileptic drug (AED), poses a therapeutic challenge
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targets [1,2], therapeutic hypothermia [3], volatile inhalational
anesthetic agents [4,5], urgent vagal nerve stimulator (VNS)
insertion [6,7], and even electroconvulsive therapy [8].
Common AED targets include gamma-aminobutyric acid (GABA),
GABA transaminase, sodium channels, calcium channels and n-
methyl D-aspartate (NMDA) receptors [1,2]. Both sodium channel
and GABA mediated AED are the most commonly utilized medica-
tions for seizures, and form the backbone of initial therapy for
RSE [1,2,9]. Phenytoin, diphenytoin and carbamazapine are the
common sodium channel antagonists utilized in the management
of seizures [9].
Lidocaine, a class Ib anti-arrhythmic agent and local anesthetic
agent, has emerged within the pediatric literature as an AED in
neonatal status epilepticus (SE) [10,11]. Of interest, despite also
acting as a sodium channel antagonist, lidocaine has displayed
efﬁcacy in seizure control in cases of SE and RSE in the presence
of phenytoin [12].served.
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previous sodium channel antagonist administration likely stems
from the drug’s amine chain, not present in other commonly used
sodium channel based AEDs [13]. This allows binding of both
compounds with aromatic based motifs, like phenytoin and
tricyclic anti-depressants, and those with amine chain motifs,
like lidocaine, at different sites on the sodium channels leading to
a combined effect [13].
The majority of the literature to date on the use of lidocaine in
SE and RSE is based in the pediatric population, with stronger
evidence in the neonate population for its efﬁcacy. This difference
may reﬂect different stages of brain maturation and thus
responsiveness to therapy. Given this, we were curious as to the
literature on adult subjects [14–26]. The goal of our study was to
perform a systematic review of the literature to determine the
effect of lidocaine on adult SE and RSE.
2. Methods
A systematic review using the methodology outlined in the
Cochrane Handbook for Systematic Reviewers [27] was conducted.
The data was reported following the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) [28]. The review
questions and search strategy were decided upon by the primary
author (FZ) and supervisor (MW).
2.1. Search question, population, inclusion and exclusion criteria
The question posed for systematic review was: What is the
effectiveness of lidocaine for control of SE in human adults? The
inclusion age range was age 18 or older. A small number of patients
with age less than 18 were included, due to the inability to separate
their data from the adults in the parent manuscripts. All studies,
prospective and retrospective of any size based on human subjects
were included. The reason for an all-inclusive search was based on
the small number of studies of any type identiﬁed by the primary
author during a preliminary search of MEDLINE.
The primary outcome measure was electrographic seizure
control. Secondary outcome measures were patient outcome (if
reported), and adverse effects of lidocaine treatment.
Inclusion criteria were: All studies including human subjects
whether prospective or retrospective, all study sizes, adult patients
(age 18 or greater), and the use of lidocaine for seizure control in
SE. Exclusion criteria were: pediatric, non-English and animal
studies.
2.2. Search strategy
MEDLINE, BIOSIS, EMBASE, Global Health, SCOPUS, and
Cochrane Library from 1946 (inception) to November 2014 were
searched using individualized search strategies for each database.
The search strategy for MEDLINE can be seen in Appendix A of the
supplementary material, with a similar search strategy utilized
for the other databases. In addition, the World Health Organiza-
tions International Clinical Trials Registry Platform was searched
looking for studies planned or underway.
As well, meeting proceedings for the last 10 years, looking for
ongoing and unpublished work based on lidocaine use for seizures,
were examined. The meeting proceedings of the following
professional societies were searched: Canadian Neurological
Sciences Federation (CNSF), American Association of Neurological
Surgeons (AANS), Congress of Neurological Surgeons (CNS),
European Neurosurgical Society (ENSS), World Federation of
Neurological Surgeons (WFNS), American Neurology Association
(ANA), American Academy of Neurology (AAN), American Epilepsy
Society (AES), European Federation of Neurological Science (EFNS),World Congress of Neurology (WCN), Society of Critical Care
Medicine (SCCM), Neurocritical Care Society (NCS), and the World
Federation of Societies of Intensive and Critical Care Medicine
(WFSICCM), American Society for Anesthesiologists (ASA), World
Federation of Societies of Anesthesiologist (WFSA), Australian
Society of Anesthesiologists, International Anesthesia Research
Society (IARS), Society of Neurosurgical Anesthesiology and Critical
Care (SNACC), Society for Neuroscience in Anesthesiology and
Critical Care, and the Japanese Society of Neuroanesthesia and
Critical Care (JSNCC).
Finally, reference lists of any review articles or systematic
reviews on seizure management were reviewed for relevant
studies on lidocaine usage for seizure control.
2.3. Study selection
Utilizing two reviewers (FZ and KZ), a two-step review of all
articles returned by our search strategies was performed. First, the
reviewers independently screened all titles and abstracts of the
returned articles to decide if they met the inclusion criteria.
Second, full text of the chosen articles was then assessed to conﬁrm
if they met the inclusion criteria and that the primary outcome of
seizure control was reported in the study. Any discrepancies
between the two reviewers were resolved by a third independent
reviewer (MW).
2.4. Data collection
Data was extracted from the selected articles and stored in an
electronic database. Data ﬁelds included: patient demographics,
type of study (prospective or retrospective), number of patients,
dose and route of lidocaine used, timing to administration of drug,
duration of drug administration, time to effect of drug, how many
other AEDs were utilized prior to lidocaine, degree of seizure
control, adverse effects, and patient outcome.
2.5. Quality of evidence assessment
Assessment of the level of evidence for each included study was
conducted by two independent reviewers (FZ and MW), utilizing
the Oxford criteria [29] and the Grading of Recommendation
Assessment Development and Education (GRADE) criteria [30–35]
for level of evidence.
The Oxford criteria consist of a 5 level grading system for
literature. Level 1 is split into subcategories 1a, 1b, and 1c which
represent a systematic review of randomized control trials (RCT)
with homogeneity, individual RCT with narrow conﬁdence
interval, and all or none studies respectively. Oxford level 2 is
split into 2a, 2b, and 2c representing systematic review of cohort
studies with homogeneity of data, individual cohort study or low
quality RCT, and outcomes research respectively. Oxford level 3 is
split into 3a and 3b representing systematic review of case-control
studies with homogeneity of data and individual case-control
study respectively. Oxford level 4 represents case-series and poor
cohort studies. Finally, Oxford level 5 represents expert opinion.
The GRADE level of evidence is split into 4 levels: A, B, C and D.
GRADE level A represents high evidence with multiple high quality
studies having consistent results. GRADE level B represents
moderate evidence with one high quality study, or multiple low
quality studies. GRADE level C evidence represents low evidence
with one or more studies with severe limitations. Finally, GRADE
level D represents very low evidence based on either expert
opinion or few studies with severe limitations.
Any discrepancies between the grading of the two reviewers
were resolved via discussion and a third reviewer when required
(CK).
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A meta-analysis was not performed in this study due to the
heterogeneity of data within the articles and the presence of a
small number of predominantly retrospective studies.
3. Results
The results of the search strategy across all databases and other
sources are summarized in Fig. 1. Seven hundred twenty-seven
articles were identiﬁed, with 718 from the database search and
9 from the search of published meeting proceedings. Seventy-two
duplicate references were removed, leaving 655 for analysis. By
applying the inclusion/exclusion criteria to the title and abstract of
the articles, we identiﬁed 65 articles that ﬁt these criteria. Upon
review of the reference sections of relevant review articles,
5 additional articles were added, leaving a total of 70 articles for
second review. Of the 70 identiﬁed, 61 were from the database
search and 9 were from published meeting proceedings. Applying
the inclusion/exclusion criteria to the full text documents, only
13 articles were eligible for inclusion in the systematic review,
with 11 from database and 2 from meeting proceeding sources.
The 57 articles that were excluded were done so because they
either did not report details around the administration of lidocaine
for seizure control, were based on pediatric patients only, were
non-relevant studies, or because they were review articles.Fig. 1. Flow diagram Of the 13 articles included in the review, all were original
studies. There were 10 retrospective studies [14–21,25,26] and
3 prospective studies [22–24]. Within the retrospective studies,
6 were retrospective case series [14,15,17–19,25] and the
remaining 4 were retrospective case reports [16,20,21,26]. All
studies were based at single centers. The 3 prospective studies
included in the systematic review were all prospective single arm
studies with no control groups [22–24].
Across all studies, 76 patients were studied utilizing lidocaine
for control of their SE/RSE (mean: 5.5 patients/study; range: 1–36
patients/study), with a total of 82 separate episodes of SE/RSE
treated with lidocaine being documented. The age of patients
studied ranged from 15 to 89 years. Two studies had small
numbers of pediatric data included with their adult patients, which
was inseparable [18,22]. This small number of pediatric patients
(lowest recorded age of 15) were included as ‘‘adults’’ for the
purpose of this study. One study failed to indicate the age of the
participants [19], though it is suspected they were adult base on
the pathology described. Study demographics and patient char-
acteristics for the adult studies can be seen in Table 1, while
treatment characteristics and seizure outcome are reported in
Table 2.
The underlying pathology leading to SE/RSE within the 76 cases
identiﬁed included: ischemic stroke (24), primary epilepsy (12),
traumatic brain injury (TBI) (5), tumor (4), post-operative SE (4),
infectious (3), idiopathic (3), metabolic (2), hypoxia (2), intracere-
bral hemorrhage (ICH) (1), and unspeciﬁed (16).of search results.
Table 1
Adult study characteristics and patient demographics.
Reference Number of
patients
treated with
lidocaine
Study type/
design
Study setting Article
location
Mean age
(years)
Etiology of seizures Mean # Meds prior
to lidocaine
Mean time until
lidocaine
administration
(days)
Aggarwal and
Wali [14]
3 Retrospective
case series
Single center Journal 30.0 (range:
30–50)
Idiopathic (1); primary
epilepsy (1); TBI (1)
2 Unknown
Bernhard et al. [15] 9 Retrospective
case series
Single center Journal 34.8 (range:
20–68)
Primary epilepsy (3);
post-op SE (4); tumor
(1); TBI (1)
Unknown 3–48 h
Cervenka et al.
[16]
1 Retrospective
case report
Single center Journal 49 Inﬂammatory cerebritis 12 (including 4 IV
anesthetics)
12 days
De Giorgio et al.
[17]
2 Retrospective
case series
Single center Journal 23 and 37 Primary epilepsy (1);
tumor (1)
4 and 2 (both had
1 IV anesthetic)
Unknown
Lemmen et al.
[18] a
4 Retrospective
case series
Single center Journal 15–61 Primary epilepsy (3);
SDH (1)
2.3 (range: 1–3) Unknown
Moddel et al.
[19]
6 Retrospective
case series
Single center Meeting
abstract
Unknown Stroke (1); hypoxia
post-arrest (2); AIDS
(1); tumor (1);
unknown (1)
Range: 2–5 (2 IV
anesthetics in 5,
3 in 1)
Unknown
Morris [20] 1 Retrospective
case report
Single center Journal 83 ICH 3 48 h
Nandakumar et al.
[21]
1 Retrospective
case report
Single center Meeting
abstract
24 NORSE 6 (3 IV anesthetics) 14 days
Pascual et al.
[22] a
36 Prospective
single arm
Single center Journal 16–89 Cerebrovascular (23);
metabolic (2); not
speciﬁed (11)
29/36 generalized SE
7/36 focal SE
2 (range: 1–2) 20 min
Pascual et al.
[23]
8 Prospective
single arm
Single center Journal 69 (range:
25–87)
Unknown (5); tumor
(1); primary epilepsy
poor medication
adherence (1);
meningitis (1)
6/8 generalized SE
2/8 focal SE
1.4 (range: 0–3) Unknown
Taverner and
Bain [24]
3 Prospective
single arm (12
injections
during 12
seizure
episodes –
randomly
assigned
placebo or
lidocaine)
Single center Journal 49.7 (range:
31–65)
Primary epilepsy (3) 1 (range: 0–3)
Fernandez-Torre
et al. [25]
1 (6 patients
total, only 1
received lido)
Retrospective
case series
Single center Journal 59 Post-TBI (focal SE) 8 Unknown
Westreich and
Kneller [26]
1 Retrospective
case report
Single center Journal 45 Post-TBI (focal SE) 4 48 h
AED = anti-epileptic drug; IV = intravenous; TBI = traumatic brain injury; SE = status epilepticus; SDH = subdural hematoma; ICH = intracerebral hemorrhage; NORSE = new
onset resistant status epilepticus; min = minute; h = hours.
a Lemmen et al. [18] and Pascual et al. [22] are studies containing small numbers of pediatric patients, of which the data cannot be extracted from the adult information.
Thus these studies were considered to be adult studies, with the pediatric data included in the analysis.
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[16–18,20,25,26], Spain [22,23,25], UK [21,24], Germany [19],
India [14], and Sweden [15].
3.1. Lidocaine treatment characteristics
Duration of treatment prior to lidocaine administration was
documented in 6 studies, ranging from 20 min to 14 days, with
patients on various numbers of AEDs prior to lidocaine, with the
mean number of AEDs ranging from 1 to 12 with most patient
treatments typically consisting of a combination of oral AED and
intravenous anesthetic agents. Of note, in 69 of the 82 (84.1%) SE/
RSE episodes described, phenytoin was on board during lidocaine
administration. All AED’s reported were typically on board during
the lidocaine treatment. Similarly, the duration of lidocaine
treatment was described in 7 of the 13 studies, with treatmentduration ranging from one time bolus dosing, up to 84 h
continuous intravenous infusion. No one was discharged home
on lidocaine therapy for their seizures.
The literature on lidocaine use for control of SE/RSE in the
adult population yielded 13 studies. Within these 13 studies
[14–26], 6 utilized bolus dosing of lidocaine in isolation
[14,15,19,23,24,26], ranging from 100 to 400 mg IV, with a
common weight based dosing of 1–3 mg/kg. One study utilized
continuous infusions of lidocaine only [19], with dosing ranging
from 2 to 4 mg/kg/h.
Finally, some studies utilized only bolus dosing of lidocaine,
followed by continuous infusions [15,17,19,20,22]. The initial
bolus ranged from 25 mg up to 3 mg/kg intravenously,  with the
number of boluses received prior to the initiation of infusion
ranging from 1 to 4. The infusion rates ranged up to 3 mg/kg/h.
Lidocaine treatment characteristics can be seen in Table 2.
Table 2
Adult articles–lidocaine treatment characteristics, seizure response, and outcome.
Reference Number of
patients
treated
with
lidocaine
Lidocaine dose Mean duration
of lidocaine
administration
(days)
PHT on
board
Electrographic seizure response Recurrence after withdrawal
of lidocaine
Adverse effects
to lidocaine
Patient outcome
Aggarwal and Wali
[14]
3 100mg IV over 1min Single bolus
dose
3/3 Seizure control in all within 45s Unknown; 1 case controlled
for 12h after single dose
None Unknown (2);
died (1)
Bernhard et al. [15] 9 7 had infusions: 1–3mg/kg/h
2 had bolus dose: 0.6–3mg/kg
once
Infusions:
12–24h
0/9 Seizures control in 7/9
Failure in 2/9
3 had recurrences None Unknown
Cervenka et al. [16] 1 Unknown Unknown 1/1 Failed N/A None Seizure control
with ketogenic
diet and surgery
De Giorgio et al. [17] 2 1mg/kg IV bolus followed by
infusion 1–2mg/min
Unknown 1/2 Seizure control within 1h None None Unknown
Lemmen et al. [18] a 4 1 patient bolus: 30mg
3 patients: combination 30mg
bolus and infusion 100–300mg/
h
Infusions:
8–48h
4/4 Seizure control in all None None Unknown
Moddel et al. [19] 6 Continuous infusion: 2–4mg/kg/
h
Unknown 6/6 4/6 seizure control
2/6 no response
¼ with control recurred with
withdrawal
None Unclear: dead
(1); palliative
care (1);
unknown (4)
Morris [20] 1 25mg4 over 15min, then
2mg/min infusion
84h 1/1 Seizure control None None Independent
Nandakumar
et al. [21]
1 Unknown Unknown 1/1 No response No response None described Died
Pascual et al. [22] a 36 (42 episodes
of SE)
Group A: Respiratory depressed
group
- No benzo
Group B: Normal Resp status
- Received benzo upfront
Lidocaine: bolus 1.5–2mg/kg2,
if not response infusion at 3–
4mg/kg/h
Unknown 42/42
episodes
First Bolus (n=42):
- 12 complete responses
- 19 temporary response
- 11 no response
Second Bolus (n=30):
- 12 complete response
- 7 temporary
- 11 no response
Infusion (n=8):
- 3 no response
- 3 complete response
- 2=50% reduction in seizures
23/42 complete response no
recurrence
14/42 no response
2/42 50% reduction
3/42 recurred after withdrawal
Hypotension (2)
Cardiorespiratory
arrest (1):
prolonged
uncontrolled RSE,
6h of lidocaine
infusion achieved
control, but patient
arrested
Dead (5);
unknown in
remaining (27)
Pascual et al. [23] 8 100mg IV bolus 1 or 2 times (7)
Infusion (1) =dose not speciﬁed
Bolus dosing (7); infusion
(1) =duration
not speciﬁed
8/8 Complete response in 5:
- 2bolus =3
Failure (temporary response) in
3
Time to response: 3min–6h
Infusion patient recurred
after withdrawal (1)
Temporary response in 2 with
single bolus
Cardiac arrest in 1
patient 6h after
2nd bolus dose.
Unclear:
1 =home,
1 =died,
6 =unknown
Taverner and
Bain [24]
3 200–400mg IV bolus
doses =6 doses in total
Each patient also received
6 random doses of
placebo= saline
Bolus only 0/3 ‘‘Increases interval between ﬁts’’
– statistically signiﬁcant
compared to placebo
Linear relationship of dose to
response
In all 3 patients None Unknown
Fernandez-Torre
et al. [25]
1 Unknown Unknown 1/1 No response No response None described Died
Westreich and
Kneller [26]
1 150mg bolus, then 1g IV over
1h, then 1g IV over 6h
1h 1/1 Seizure cessation in 5min No recurrence None Home
mg=milligram; kg=kilogram; h=hour; min=minute; IV= intravenous; SE= status epilepticus; RSE= refractory status epilepticus.
a Lemmen et al. [18] and Pascual et al. [22] are studies containing small numbers of pediatric patients, of which the data cannot be extracted from the adult information. Thus these studies were considered to be adult studies, with
the pediatric data included in the analysis.
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Table 3
Adult studies – Oxford and GRADE level of evidence.
Reference Study type Oxford [29]
level of
evidence
GRADE
[30–35]
level of
evidence
Aggarwal and Wali
[14]
Retrospective case series 4 D
Bernhard et al. [15] Retrospective case series 4 D
Cervenka et al. [16] Retrospective case report 4 D
De Giorgio et al. [17] Retrospective case series 4 D
Lemmen et al. [18] a Retrospective case series 4 D
Moddel et al. [19] Retrospective case series 4 D
Morris [20] Retrospective case series 4 D
Nandakumar et al.
[21]
Retrospective case series 4 D
Pascual et al. [22] a Prospective single arm 2b C
Pascual et al. [23] Prospective single arm 4 D
Taverner and Bain
[24]
Prospective single arm 4 C
Fernandez-Torre
et al. [25]
Retrospective case series 4 D
Westreich and
Kneller [26]
Retrospective case report 4 D
a Lemmen et al. [18] and Pascual et al. [22] are studies containing small numbers
of pediatric patients, of which the data cannot be extracted from the adult
information. Thus these studies were considered to be adult studies, with the
pediatric data included in the analysis.
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Overall, 58 of the 82 (70.7%) SE/RSE episodes studied displayed
seizure response to lidocaine administration. Complete seizure
control upon lidocaine administration occurred in 53 of the 82
(64.6%) SE/RSE episodes documented. A greater than 50% reduction
in seizure frequency occurred in 5 of the 82 (6.1%) SE/RSE episodes
described. Failure of lidocaine treatment occurred in 24 of 82
(29.2%) episodes.
In those patients with phenytoin on board during lidocaine
administration, there were 69 discrete SE/RSE episodes recorded.
Lidocaine administration resulted in seizure reduction in 47 of
these 69 (68.1%) episodes, with 45 of 69 (65.2%) and 2 of 69 (2.9%)
resulting in complete seizure control and greater than 50% seizure
reduction, respectively. Twenty-two of these 69 (31.9%) SE/RSE
episodes failed lidocaine administration when phenytoin was
already on board.
Within the group of patients treated with lidocaine in the
absence of phenytoin on board there were 13 discrete SE/RSE
episodes described. Complete seizure cessation with lidocaine
administration occurred in 8 of the 13 (61.5%) SE/RSE episodes.
Three of the 13 (23.1%) SE/RSE episodes treated with lidocaine
resulted in greater than 50% reduction in seizures. Failure of
lidocaine therapy occurred in 2 of the 13 (15.4%) of the SE/RSE
episodes described.
Recurrence of seizures upon withdrawal of lidocaine occurred
in 13 of the 58 (22.4%) responsive SE/RSE episodes.
3.3. Adverse effects of lidocaine
Only two studies documented adverse events related to
lidocaine administration [22,23]. One study displayed 2 cases of
hypotension with lidocaine bolus dosing [22]. Cardiorespiratory
arrest was seen in 2 patients [22,23]. One patient had received 6 h
of continuous lidocaine infusion with control of RSE around the 6 h
mark from onset. The patient arrested with failed resuscitation
attempts [22]. The second patient suffered a fatal cardiac arrest 6 h
after 2 bolus doses of lidocaine were administered [23].
3.4. Outcome
Patient outcome was reported sparingly in most studies as the
main focus of these reports was the success/failure of lidocaine
treatment. This data can be seen in Table 2.
3.5. Level of evidence for lidocaine
Based on two independent reviewers, there were a total of
13 studies reviewed with 12 representing Oxford level 4 evidence
for the administration of lidocaine for SE/RSE [14–21,23–26].
One prospective single arm study was deemed Oxford level 2b
evidence for the administration of lidocaine for SE/RSE.
Eleven of 13 studies met GRADE D level of evidence [14–21,
23,25,26], while the remaining 2 met GRADE C level of evidence
[22,24]. Summary of the level of evidence can be seen in Table 3.
4. Discussion
Lidocaine is a type Ib anti-arrhythmic agent and sodium
channel antagonist commonly utilized in the cardiac and pain
literature. It is via its sodium channel blockage that neural
conduction is reduced and impeded, leading to its anti-arrhythmic
and anesthetic properties. Given these effects at the neuronal
sodium channel, lidocaine’s role as an AED has been investigated
[12,14–26].Unlike other sodium channel blocking AEDs, such as phenytoin
(also a class Ib anti-arrhythmic), its structure includes an aromatic
and amine chain motif allowing for binding to the sodium channel
via both the channels pore-lining phenyl binding site [36,37], or via
the external amine chain site, both of which lead to the reduction
of ion transport across the cellular membrane. Other sodium
channel based AEDs typically only carry a diphenyl motif, solely
allowing binding at the pore-lining phenyl sites [13], blocking
sodium ion transport. Thus, lidocaine can potentially add further
sodium channel blockade in the setting of refractory seizures
where other sodium channel antagonists are on board, via
interaction with the external amine binding site.
To date small case series have appeared since the 1950s
describing the use of lidocaine as an AED, with the majority of
the literature focused on the pediatric population. Current
literature suggests a trend to improved responsiveness in the
neonate population, which may suggest a differential response
rate depending on the degree of brain maturation. This however
has yet to be substantiated. Given the success of lidocaine as
an AED in the setting of neonatal and pediatric seizures [10–12],
we elected to perform a systematic review of the literature in
order to determine its effect on SE and RSE in the adult population.
Through our review we identiﬁed 13 articles pertaining to the
reported usage of lidocaine for adult SE/RSE [14–26], with
11 published manuscripts and 2 published meeting abstracts. A
total of 76 patients were described in these articles, with 82 distinct
episodes of SE/RSE being treated with lidocaine. The majority of the
studies were retrospective case reports/series, with only 3 being
prospective single arm studies. Looking at the primary outcome
of our study (seizure control), 70.7% of these SE/RSE episodes
responded to lidocaine administration, with 64.3% complete
seizure control rates. Of interest, during 69 of the SE/RSE episodes,
phenytoin was on board during lidocaine administration, with
68.1% displaying seizure response to lidocaine. Recurrence of
seizures after lidocaine withdrawal occurred in 22.4% of SE/RSE
episodes. In the secondary outcomes, few adverse events were
reported with lidocaine administration, though those reported
were signiﬁcant. Patient outcome data was too sparingly
documented for any conclusions to be made. Twelve studies were
F.A. Zeiler et al. / Seizure 31 (2015) 41–48 47Oxford level 4 for quality, with one representing Oxford level 2b.
Eleven studies were GRADE D, with 2 representing GRADE C
level of evidence. A meta-analysis was not possible given the
heterogeneous nature of the studies available. Thus, based on this
review, we can currently provide Oxford level 4, GRADE C
recommendations for the use of lidocaine for adult SE/RSE. This
constitutes weak evidence to support the use of lidocaine in this
context. The current lack of more robust studies impairs our ability
to draw more deﬁnitive conclusions on the impact of lidocaine
for SE/RSE in adults.
Some important points have arisen from our review. First, the
seizure response rate of 70.7% with lidocaine administration in a
population of medically refractory cases is quite high compared to
other therapies for RSE [38]. This likely represents a signiﬁcant
publication bias, focused on publishing only positive results with
lidocaine for SE/RSE. Second, the seizure cessation rate of 65.2% in
response to lidocaine when phenytoin has already been adminis-
tered highlights the effectiveness of this medication in the
presence of another sodium channel agent, as further emphasized
by the 61.5% cessation rate for those patients not on phenytoin
during lidocaine therapy. This likely represents the effect of the
external sodium channel binding motif of lidocaine, not possessed
by other sodium channel AEDs. Third, the seizure recurrence with
withdrawal of lidocaine therapy was 22.4%, emphasizing that this
treatment is not a long-term solution, but an option during crisis.
Seizure response to lidocaine should be met with ongoing
adjustment of oral AEDs with the goal of discontinuing intravenous
anesthetic agents. Fourth, there did not appear to be a trend to
increased efﬁcacy in any particular underlying etiology treated
within the studies. Fifth, the majority of the studies originated in
the USA or Western Europe. This is slightly different when
compared to those in the neonate populations which have a
Japanese predominance. Thus, there may be a potential for regional
variation in the application and response of lidocaine for SE/RSE.
Finally, the number of complications described was low, with only
two patients developing hypotension. The two cases of cardiore-
spiratory arrest during the treatment of RSE are difﬁcult to solely
attribute to lidocaine therapy given the complexity of treatment
and critical illness. However, given that we cannot completely
exclude lidocaine as the cause of arrest given the available data, we
include these two cases as complications of therapy.
Our review has signiﬁcant limitations. First, the small number
of studies identiﬁed, all with small patient populations, makes it
difﬁcult to generalize to all adult SE/RSE patients. Second, the
predominantly retrospective heterogeneous nature of the data
makes it difﬁcult to perform a meaningful meta-analysis, resulting
in a strictly descriptive analysis. Third, the heterogeneity of prior
treatments, time to lidocaine administration, and lidocaine dosage
and duration leave the data on seizure responsiveness difﬁcult to
interpret. It is even more difﬁcult, on the basis of this data, to
recommend a treatment regimen based on lidocaine. Fourth, the
outcome data was poorly recorded in the majority of the studies
identiﬁed. As such, formal comments on the impact of lidocaine
therapy on patient outcome during SE/RSE cannot be made at this
time. Fifth, a small number of pediatric patients may have been
included in the synthesis of data, and thus our results may not
reﬂect an entirely ‘‘adult’’ population. Two manuscripts describe
patients under the age of 18 [18,22], however we were unable to
separate their data from the adult population. Similarly, one study
[19] failed to document the age of the patients. Though we suspect,
based on the pathology described, that these patients were adults,
they very well may be younger than 18 years of age. Sixth, the
range of ages seen in this review is important. There may be a
correlation of responsiveness to lidocaine and the degree of brain
maturation. Thus, younger patients may be more adept to
responding, as seen in the neonates, whereas the elderly maynot be as responsive. We were unable to determine a trend to
responsiveness in younger adult patients however. This is an area
of potential future research. Seventh, we intentionally excluded
non-English manuscripts from the review. Though we did not
identify any abstracts of non-English origin that may have been of
interest, we may have missed some non-English manuscripts in
the process which focused on lidocaine for SE/RSE in adults. As a
result, our review may not be entirely inclusive. Finally, as
previously mentioned, there is likely a signiﬁcant publication bias
in the literature favoring the publication of only positive results
with lidocaine therapy for adult SE/RSE. Despite these signiﬁcant
limitations, we believe the data provides evidence for the potential
beneﬁt of lidocaine therapy in the setting of adult SE/RSE.
Future prospective analysis of lidocaine treatment during adult
SE/RSE should be conducted. Formal comparison between
phenytoin and lidocaine in a randomized fashion may prove
interesting. Furthermore, prospective evaluation of lidocaine as
the 3rd line agent in adult SE/RSE, in comparison to other
commonly utilized agents should be conducted. In addition, there
exists room for multicenter RCT in RSE comparing lidocaine to
other commonly utilized agents such as midazolam or thiopen-
tone. Prior to embarking on such endeavors however, we need to
outline a means for accurate and comprehensive outcome
assessment, as this is currently lacking in the available literature.
5. Conclusions
There currently exists level 4, GRADE C evidence to support the
consideration of lidocaine for SE and RSE in the adult population.
This constitutes weak evidence to support the use of lidocaine in
this context. Further prospective studies of lidocaine administra-
tion in this setting are warranted.
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